In this study, we focused on comparing the effects of serotonin and its metabolites on the functions of RAW264.7 cells (emphasis on oxidative burst and production of nitric oxide and cytokines), thereby expanding the scope of existing knowledge with advent of novel findings in this field. Changes in production of reactive oxygen species (ROS) by RAW264.7 cells after treatment with serotonin, N-acetylserotonin and melatonin were determined using the chemiluminescence (CL) assay. To exclude the direct scavenging effects of the studied compounds on the CL response, the antioxidant properties of all respective compounds were measured using TRAP and amperometrical method. Nitric oxide (NO) production was measured by Griess reagent and inducible NO synthase (iNOS) expression by Western blot. Cytokine production was assessed using the Mouse Cytokine Panel A Array kit and ELISA. We showed that all tested compounds were able to reduce oxidative stress, as well as inhibit production of inflammatory cytokines by macrophages. Of the tested compounds, serotonin and N-acetylserotonin were markedly better antioxidants than melatonin. In comparison, other effects of tested compounds were very similar. It can be concluded that antioxidant capacity of tested compounds is a major advantage in the early stages of inflammation. Since plasma concentrations of N-acetylserotonin and melatonin are lower than serotonin, it can be deduced that serotonin plays a key role in modulation of inflammation and the regulatory functions of immune cells, while also protecting cells against oxidative stress.

Department of Animal Physiology and Immunology Institute of Experimental Biology Masaryk University Kotlarska 2 611 37 Brno Czech Republic

Institute of Biophysics of the Czech Academy of Sciences Kralovopolska 135 612 65 Brno Czech Republic

Zobrazit více v PubMed

Carbohydr Polym. 2017 Nov 1;175:178-191 PubMed

ScientificWorldJournal. 2011;11:2443-57 PubMed

J Infect Dis. 1997 Jun;175(6):1404-12 PubMed

J Pineal Res. 2013 Sep;55(2):103-20 PubMed

Br J Pharmacol. 2003 May;139(2):457-63 PubMed

Int Immunopharmacol. 2001 Aug;1(8):1397-406 PubMed

Life Sci. 1988;42(17):1641-50 PubMed

Thromb Res. 1999 Jul 1;95(1):1-18 PubMed

Eur J Pharmacol. 2015 Apr 15;753:2-18 PubMed

FEBS Lett. 1999 Apr 23;449(2-3):206-10 PubMed

Curr Med Chem. 2011;18(34):5281-8 PubMed

Nat Immunol. 2001 Oct;2(10):907-16 PubMed

Blood. 2013 Feb 7;121(6):1008-15 PubMed

J Vet Pharmacol Ther. 2008 Jun;31(3):187-99 PubMed

J Immunol. 1987 Jun 15;138(12):4360-5 PubMed

Pharmacology. 2016;97(3-4):195-206 PubMed

Int Immunol. 2005 May;17(5):599-606 PubMed

Eur J Clin Invest. 1995 Jul;25(7):477-84 PubMed

Front Cardiovasc Med. 2017 Jul 20;4:48 PubMed

Life Sci. 2014 Mar 28;100(1):67-72 PubMed

J Neuroimmunol. 1999 Sep 1;99(1):53-60 PubMed

Acta Biochim Pol. 2014;61(2):359-67 PubMed

Ann N Y Acad Sci. 2005 Aug;1053:334-47 PubMed

J Pineal Res. 2009 Apr;46(3):268-74 PubMed

J Pharmacol Exp Ther. 2008 Nov;327(2):316-23 PubMed

Br J Pharmacol. 2014 Jan;171(1):134-44 PubMed

Anal Biochem. 2004 May 1;328(1):14-21 PubMed

Immunology. 2004 Nov;113(3):281-92 PubMed

Biochem J. 1993 Feb 15;290 ( Pt 1):51-7 PubMed

Interdiscip Toxicol. 2011 Mar;4(1):15-9 PubMed

J Pineal Res. 2006 Sep;41(2):136-41 PubMed

Neuropsychopharmacology. 2000 Jul;23(1):89-98 PubMed

Platelets. 2007 Dec;18(8):583-90 PubMed

Br J Pharmacol. 1995 Aug;115(7):1175-81 PubMed

Neuroimmunomodulation. 2007;14(3-4):126-33 PubMed

PLoS One. 2009 Jul 31;4(7):e6453 PubMed

J Leukoc Biol. 2004 Jun;75(6):1116-21 PubMed

Cell. 2003 Dec 26;115(7):851-62 PubMed

Acta Physiol (Oxf). 2015 Mar;213(3):561-74 PubMed

J Neuroimmunol. 2006 Dec;181(1-2):68-81 PubMed

Blood. 2006 Jul 15;108(2):518-24 PubMed

J Biol Chem. 1959 Apr;234(4):858-64 PubMed

Int Immunol. 2003 Feb;15(2):233-40 PubMed

J Immunol. 1993 Aug 1;151(3):1175-83 PubMed

Trends Immunol. 2015 Mar;36(3):161-78 PubMed

J Pineal Res. 1999 Oct;27(3):159-63 PubMed

FASEB J. 2004 Mar;18(3):537-9 PubMed

J Interferon Res. 1992 Jun;12(3):199-206 PubMed

Neuropharmacology. 1999 Aug;38(8):1083-152 PubMed

Clin Exp Immunol. 2006 Nov;146(2):354-61 PubMed

Acta Physiol Scand Suppl. 1964;:SUPPL 232:1-55 PubMed

Brain Behav Immun. 1998 Dec;12(4):249-71 PubMed

Life Sci. 2010 Mar 27;86(13-14):518-23 PubMed

Adv Exp Med Biol. 1996;398:299-306 PubMed

J Chromatogr. 1992 Sep 2;579(2):340-5 PubMed

Scand J Immunol. 1993 Jan;37(1):7-18 PubMed

Chem Rev. 2008 May;108(5):1614-41 PubMed

Psychiatry Res. 2005 Apr 30;134(3):251-8 PubMed

Immunol Rev. 2000 Feb;173:17-26 PubMed

Pharmacol Res. 2019 Feb;140:100-114 PubMed

Adv Exp Med Biol. 1999;467:321-5 PubMed

Int J Mol Sci. 2013 Apr 22;14(4):8638-83 PubMed

Arch Oral Biol. 2017 Oct;82:11-18 PubMed

Eur J Pharmacol. 2004 Oct 6;501(1-3):25-30 PubMed

J Immunol. 1986 Jul 1;137(1):276-82 PubMed

Ann N Y Acad Sci. 2005 Aug;1053:386-93 PubMed

CNS Spectr. 2014 Dec;19 Suppl 1:57-67; quiz 54-7, 68 PubMed

Mol Neurobiol. 2004 Feb;29(1):31-9 PubMed

Shock. 1998 Jun;9(6):406-11 PubMed

Eur J Pharmacol. 1997 Oct 29;338(1):97-104 PubMed

Br J Pharmacol Chemother. 1968 Jan;32(1):1-16 PubMed

FASEB J. 1998 Jun;12(9):685-93 PubMed

J Chromatogr B Biomed Sci Appl. 2000 Sep 29;747(1-2):33-48 PubMed

Brain Cogn. 2009 Dec;71(3):427-36 PubMed

Endocrine. 2005 Jul;27(2):189-200 PubMed

Cyanobacterial Harmful Bloom Lipopolysaccharides Induce Pro-Inflammatory Effects in Immune and Intestinal Epithelial Cells In Vitro

Structural Features and Immunomodulatory Effects of Water-Extractable Polysaccharides from Macrolepiota procera (Scop.) Singer

Pseurotin D Induces Apoptosis through Targeting Redox Sensitive Pathways in Human Lymphoid Leukemia Cells

Pseurotin D Inhibits the Activation of Human Lymphocytes